Among the clinical variables considered for patients, severity of negative symptoms was correlated with reduced P3b (350) for targets (r = −0.43, p = 0.02) and novels (r = −0.53, p = 0.005), and reduced FRN (505) source at centro-parietal sites for targets was correlated with severity of general symptoms (r = −0.47, p = 0.01) and poorer global assessment of function (r = 0.37, p = 0.05). Reduced N1 ERS was associated with severity of negative symptoms (for targets, r = −0.50, p = 0.008) and poorer global assessment of function (for targets, r = 0.46, p = 0.02; for nontargets, r = 0.47, p = 0.01).
